Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152351 | 0.92 | L3MBTL1 (0.41) | KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6153623 | 0.79 | KDM4E (0.43) | KDM4ETSHRALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL6152429 | 0.78 | ALDH1A1 (0.53) | POLBKDM4EKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6152949 | 0.76 | PLAAT3 (0.35) | MAPT | |
| SCHEMBL6153006 | 0.74 | ALDH1A1 (0.57) | POLBKDM4ETSHRKMT2AMEN1 | |
| SCHEMBL6153686 | 0.73 | ALDH1A1 (0.47) | POLBKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL6152350 | 0.69 | HPGD (0.39) | KDM4ETSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6152322 | 0.68 | LTA4H (0.51) | KDM4EKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6152882 | 0.68 | POLB (0.39) | POLBKDM4ETP53TSHRKMT2A | |
| SCHEMBL7245208 | 0.68 | POLB (0.39) | POLBKDM4ETP53TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | POLB 4177/4885KDM4E 1330/4885TP53 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.